Skip to main content

Gallium ga 68 dotatate Pregnancy and Breastfeeding Warnings

Gallium ga 68 dotatate is also known as: Netspot

Gallium ga 68 dotatate Pregnancy Warnings

There are no controlled data in human pregnancy. The estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively.

Safety has not been established during pregnancy.

Risk Summary:
-There are no studies in pregnant women to inform any drug-associated risks; however, all radiopharmaceuticals, including this drug have the potential to cause fetal harm.

See references

Gallium ga 68 dotatate Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comment: Interrupt breastfeeding and pump and discard breast milk for 12 hours after administration of this drug to minimize radiation exposure to a breastfed infant.

See references

References for pregnancy information

  1. "Product Information. Netspot (dotatate)." Advanced Accelerator Applications (2016):

References for breastfeeding information

  1. "Product Information. Netspot (dotatate)." Advanced Accelerator Applications (2016):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.